GLP1R and neoplasm: Compared with placebo only, GLP-1 receptor agonist use was not associated with an increased incidence of neoplasia (OR 1.04, 95% CI 0.94–1.16; p = 0.46), and no statistically significant between-study heterogeneity was observed (I2 = 0%, p = 0.58; Figure 5).